NASDAQ:TELA TELA Bio Q3 2026 Earnings Date & Estimates $0.86 +0.06 (+8.09%) As of 02:31 PM Eastern This is a fair market value price provided by Massive. Learn more. TELA Bio is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026Conference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from TELA Bio in Q3 2026TELA Bio is expected to post earnings of -$0.19 per share on revenue of $20 million. In the same quarter a year earlier TELA Bio reported -$0.19 per share on revenue of $20.69 million. TELA Bio last reported on August 10, 2026, posting -$0.20 per share and missing the -$0.1738 consensus estimate. TELA Bio has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.19Expected Revenue$20 millionPrior-Year EPS-$0.19Prior-Year Revenue$20.69 millionExpected Revenue Growth-3.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.20 (Missed by -$0.0262)Last Quarter Revenue$19.29 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report TELA Bio Q3 2026 Earnings FAQ When does TELA Bio report Q3 2026 earnings? TELA Bio (NASDAQ:TELA) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is TELA Bio's Q3 2026 earnings call? TELA Bio's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for TELA Bio? Analysts expect TELA Bio to post earnings of -$0.19 per share for Q3 2026. How much revenue is TELA Bio expected to report? The consensus revenue estimate for TELA Bio is $20 million for Q3 2026. TELA Bio Earnings HeadlinesTELA Bio (NASDAQ:TELA) Stock Rating Raised to Sell at Wall Street ZenOctober 31 at 1:37 AM | americanbankingnews.comTELA Bio to Announce Third Quarter 2026 Financial ResultsOctober 27, 2026 | globenewswire.comGovernment Document Reveals Plan To Control Your Money (it will disturb you)A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.November 3 at 1:00 AM | Weiss Ratings (Ad)TELA Bio, Inc. (TELA) - What Are Brokerages Thinking About This Stock?October 25, 2026 | americanbankingnews.comTELA Bio (TELA) Stock Sees Fair Value Cut As Analysts Weigh New Leadership RisksOctober 19, 2026 | finance.yahoo.comLake Street Sticks to Its Buy Rating for TELA Bio (TELA)October 16, 2026 | theglobeandmail.comSee More TELA Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TELA Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TELA Bio and other key companies, straight to your email. Email Address About TELA BioTELA Bio (NASDAQ:TELA) is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response. TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications. The company also offers products intended for plastic and reconstructive surgery and related surgical specialties. Founded in 2012 and headquartered in Malvern, Pennsylvania, TELA Bio primarily serves the U.S. surgical market through its commercial organization and distribution relationships. The company’s products are used by surgeons and hospitals seeking alternatives for soft-tissue reinforcement and reconstruction.View TELA Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings BeatCheck Point's Turnaround Could Be Closer Than Investors ThinkTempus AI Surges on Earnings Beat, But Can the Rally Last? Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
